CLYM Climb Bio, Inc.
Price Chart
Executive Summary
Climb Bio entered into a securities purchase agreement for a $110.0 million private placement, selling 9,481,000 shares at $9.50/share and 2,106,000 pre-funded warrants at $9.4999/warrant to institutional investors including RA Capital, Adage Capital, and others. The offering represents approximately 25% dilution based on the current $454M market cap and is priced at a 1.5% discount to the last trade. Proceeds extend the cash runway for late-stage development of budoprutug and CLYM116, but the dilutive financing signals the company needed capital to fund operations.
Key Financial Metrics
Actionable Insight
The $110M raise at a 1.5% discount to market is highly dilutive (~25% of current market cap) and signals the company needed capital to fund operations given its pre-revenue status. While the cash runway extension supports late-stage pipeline catalysts, the magnitude of dilution and the 0% historical win rate on prior CLYM calls suggest the stock may face continued selling pressure. Monitor for the resale registration filing within 45 days, which could enable further distribution by investors. The presence of multiple healthcare-focused funds suggests potential for near-term price support, but the dilutive overhang is significant.
Key Facts
- Aggregate gross proceeds of approximately $110.0 million from a private placement of 9,481,000 shares at $9.50/share and 2,106,000 pre-funded warrants at $9.4999/warrant
- Pre-funded warrants have an exercise price of $0.0001 per share, exercisable immediately until exercised in full
- Offering priced at $9.50 per share vs. current market cap of $454M — approximately 25% dilution
- Closing expected on or about April 29, 2026, subject to customary conditions
- Placement agents include Leerink Partners, Piper Sandler, Raymond James, BTIG, Baird, and H.C. Wainwright
- Company must file a resale registration statement within 45 days of closing, with liquidated damages of 1.0% per 30-day period for delays (capped at 5.0% of purchase price)
- RA Capital's pre-funded warrants include a 33.0% beneficial ownership limitation and remain subject to the existing Exchange Agreement requiring proportional voting for shares above 33.0%
- Cash runway extended to support late-stage development of budoprutug (anti-CD19) and CLYM116 (anti-APRIL)
- Historical performance on CLYM shows 0% win rate at T+20 on 2 settled reports, with average T+20 return of -9.89%
Financial Impact
Approximately $110.0 million gross proceeds, representing ~25% dilution on a $454M market cap. Net proceeds after placement agent fees and expenses will be lower.
Risk Factors
- Approximately 25% dilution from the offering may pressure the stock price
- Registration rights agreement allows investors to resell shares, potentially creating overhang
- Pre-funded warrants are immediately exercisable, adding further potential dilution
- Company is pre-revenue with no approved products; cash burn continues
- Historical CLYM reports show negative T+20 returns (avg -9.89%) with 0% win rate
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-183711 |
| Document: d153155dex102.htm | 0001193125-26-183711 |
| Document: d153155dex41.htm | 0001193125-26-183711 |
| Document: d153155d8k.htm | 0001193125-26-183711 |
| Document: d153155dex991.htm | 0001193125-26-183711 |
| Document: 0001193125-26-183711-index-headers.html | 0001193125-26-183711 |
| Document: 0001193125-26-183711-index.html | 0001193125-26-183711 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
4d ago
|
8-K
| $10.77 awaiting T+5 | awaiting T+5 | — | $11.14 (+3.39%) |
|
May 29, 2026
11d ago
|
S-3
| $11.80 $10.55 | ▼ −10.59% | ▼ −7.84% | $11.14 (−5.64%) |
|
May 7, 2026
4w ago
|
8-K
| $11.91 $11.41 | ▼ −4.20% | ▼ −5.70% | $11.14 (−6.51%) |
|
May 5, 2026
5w ago
|
8-K
| $11.45 $11.17 | ▼ −2.45% | ▼ −4.43% | $11.14 (−2.75%) |
|
Apr 28, 2026
6w ago
|
8-K
| $9.26 $9.69 | ▼ −4.64% | ▼ −2.95% | $11.14 (−20.25%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $9.50 $9.69 | ▲ +2.00% | ▲ +1.60% | $11.14 (+17.21%) |
|
Apr 3, 2026
9w ago
|
8-K
| $6.74 $8.63 | ▲ +28.04% | ▲ +23.91% | $11.14 (+65.21%) |
|
Mar 5, 2026
13w ago
|
8-K
| $7.39 $7.26 | ▼ −1.76% | ▲ +0.48% | $11.14 (+50.68%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $7.39 $7.26 | ▼ −1.76% | ▲ +0.48% | $11.14 (+50.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access